COMMUNIQUÉS West-GlobeNewswire

Altimmune Announces Pre-Clinical Data From its SparVax-L Anthrax Vaccine Program
12/03/2018
Single dose of vaccine showed 67% survival rate and 100% survival rate after two doses GAITHERSBURG, Md., March 12, 2018 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT ), a clinical-stage immunotherapeutics company, [...]
ERYTECH Provides Business Update and Reports Financial Results for Full Year 2017
12/03/2018
ERYTECH Provides Business Update and Reports Financial Results for Full Year 2017 Conference call and webcast on Tuesday, March 13 th at 1:30 pm CET/8:30 am EDT Reported positive data from Phase 2b clinical trial of [...]
Vascepa® (Icosapent Ethyl) Showed Reductions in Potentially Atherogenic Lipids and Inflammatory Markers in Patients With Persistent High Triglycerides and Elevated High-Sensitivity C-Reactive Protein (hsCRP)
12/03/2018
BEDMINSTER, N.J. and DUBLIN, Ireland, March 12, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN ), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve [...]
Real-World Data Supports Association Between Elevated Triglyceride Levels and Increased Cardiovascular Events and Healthcare Costs
12/03/2018
BEDMINSTER, N.J. and DUBLIN, Ireland, March 12, 2018 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ: AMRN ), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve [...]
Precision Therapeutics Appoints Kevin Hungerford as Vice President of Sales and Marketing
12/03/2018
MINNEAPOLIS, March 12, 2018 (GLOBE NEWSWIRE) -- Precision Therapeutics Inc. (NASDAQ: AIPT ) (“Precision” or “the Company”), formerly Skyline Medical, announced today that it has appointed Kevin Hungerford as Global Vice [...]
Epizyme Appoints Oncology Industry Leader Michael Giordano, M.D., to its Board of Directors
12/03/2018
CAMBRIDGE, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Epizyme, Inc. (NASDAQ: EPZM ), a clinical-stage biopharmaceutical company creating novel epigenetic therapies, today announced the appointment of Michael Giordano, M. [...]
Arch Therapeutics Provides Update on 510(k)
12/03/2018
FRAMINGHAM, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB:ARTH) ("Arch" or the "Company"), developer of liquid, gel and solid hemostatic and wound care devices, today announced that it has [...]
Scythian Biosciences Announces 4-For-1 Stock Split and Appointment of Vic Neufeld as New Chairman of the Board of Directors
12/03/2018
TORONTO, March 12, 2018 (GLOBE NEWSWIRE) -- Scythian Biosciences Corp. (the " Company " or “ Scythian ”) (TSXV:SCYB) (Frankfurt: 9SB ) (OTC – Nasdaq Intl:SCCYF) announces that, further to its press release on March 9, [...]
Radius Health to Present at ENDO 2018 Including Results of the ACTIVExtend BMD Responder Analysis for TYMLOS™ (abaloparatide) Injection
12/03/2018
WALTHAM, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Radius Health, Inc. (Nasdaq: RDUS ) a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine [...]
Vericel to Host Analyst and Investor Day on April 11, 2018
12/03/2018
CAMBRIDGE, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ: VCEL ), a leader in advanced cell therapies for the sports medicine and severe burn care markets, today announced that it will host an [...]
Teligent, Inc. to Hold Conference Call for Fourth Quarter 2017 Results
12/03/2018
BUENA, N.J., March 12, 2018 (GLOBE NEWSWIRE) -- Teligent, Inc. (NASDAQ: TLGT ), a New Jersey-based specialty generic pharmaceutical company, announced the Company will hold a conference call at 4:30pm ET on Thursday [...]
VBI Vaccines Announces Voluntary Delisting from the Toronto Stock Exchange
12/03/2018
CAMBRIDGE, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- VBI Vaccines Inc. ("VBI" or the "Company") (Nasdaq: VBIV ) (TSX: VBV ), a commercial-stage biopharmaceutical company developing next-generation infectious disease and [...]
Agile Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
12/03/2018
PRINCETON, N.J., March 12, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX ), a women's healthcare company, today reported financial results for the three months and year ended December 31, 2017 and [...]
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Fiscal Year Ended December 31, 2017
12/03/2018
RANCHO CUCAMONGA, Calif., March 12, 2018 (GLOBE NEWSWIRE) -- Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH ) (“Amphastar” or the “Company”) today reported results for the three months and fiscal year ended December 31, [...]
Proteostasis Therapeutics Announces FDA Grants Breakthrough Therapy Designation for PTI-428 in Cystic Fibrosis
12/03/2018
CAMBRIDGE, Mass., March 12, 2018 (GLOBE NEWSWIRE) -- Proteostasis Therapeutics, Inc. (NASDAQ: PTI ), a clinical stage biopharmaceutical company dedicated to the discovery and development of groundbreaking therapies to [...]
Prothena to Present a Broad Range of Scientific and Health Outcomes Data at the 16th International Symposium on Amyloidosis
12/03/2018
DUBLIN, Ireland, March 12, 2018 (GLOBE NEWSWIRE) -- Prothena Corporation plc (Nasdaq: PRTA ), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel therapies in [...]
Crinetics Pharmaceuticals Announces Upcoming Presentations at ENDO 2018
12/03/2018
SAN DIEGO, March 12, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced an oral presentation and [...]
Aquinox Pharmaceuticals Announces Year End 2017 Financial Results
12/03/2018
VANCOUVER, British Columbia, March 12, 2018 (GLOBE NEWSWIRE) -- Aquinox Pharmaceuticals , Inc. (" Aquinox ") (NASDAQ: AQXP ), a clinical-stage pharmaceutical company discovering and developing novel drug candidates to [...]
G1 Therapeutics Announces Closing of Offering of Common Stock
12/03/2018
RESEARCH TRIANGLE PARK, N.C., March 12, 2018 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a clinical-stage oncology company, today announced the closing of an underwritten public offering of 3,910,000 [...]

Pages